The Longevity Reality Radar
46 approaches, rated by evidence.

40 Hz light and sound for Alzheimer's

40 Hz gamma sensory stimulation (GENUS / Cognito) — Alzheimer's. Brain & neurodegeneration. Reviewed Sep 2026.

Strong mouse data and one small human feasibility trial, but the Phase 3 has not reported and human efficacy is not established.

Stage
Phase 3, no results yet
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
small human trial
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

A non-invasive device delivering flickering light and sound at exactly 40 Hz to entrain gamma brain waves, activate the brain's microglia and, in principle, help clear amyloid. Grew out of Li-Huei Tsai's MIT lab and is being commercialised by Cognito Therapeutics.

The evidence

Strong in mice: Tsai's team (Iaccarino et al., Nature 2016) showed 40 Hz entrainment cut amyloid load and activated microglia. In humans the data are still early and far less dramatic: a small feasibility trial (OVERTURE, Hajos et al. 2024) suggested slowed cognitive/functional decline and less brain atrophy over 6 months, and Cognito holds an FDA expedited-review designation for devices. The pivotal Phase 3 (HOPE, NCT05637801) finished enrolment in 2026 but has not reported results. Human efficacy is not yet established and independent replications of the amyloid-clearance effect have been mixed — so the viral 'the science is settled' framing is premature.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Brain & neurodegeneration

All 5 in Brain & neurodegeneration.

  • Lecanemab and donanemabGrade A, outcome RCTs. Approved.Slows cognitive decline by about 27 to 35% in early Alzheimer's, which is not a cure, and brain swelling or bleeding is a real risk.
  • GLP-1 drugs for brain healthGrade C, emerging data. Phase 2/3.Early signals of better memory, but large trials are still running and no brain benefit is proven.
  • Stem-cell therapy for Parkinson'sGrade C, small cohorts. Phase 1/2, conditional approval in Japan.Motor symptoms eased or stabilised for up to two years in small cohorts, with no large randomised results yet.
  • Psilocybin for brain agingGrade D, one case report. Speculative.A single Alzheimer's case report and preliminary lab data, not a basis for treating brain aging.